-
AMAG Pharmaceuticals Up 14% (AMAG)
Monday, November 29, 2010 - 12:47pm | 82AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) is up sharply this morning, gaining more than 14% on back of news that it came to an agreement with the FDA over labeling of its Feraheme injection drug. AMAG has agreed to a label that includes warnings about potentially life-threatening events, but...
-
Benzinga's Volume Movers (AMAG, ASYS, SPTN, AMZN)
Monday, November 29, 2010 - 12:01pm | 153AMAG Pharmaceuticals Inc (NASDAQ: AMAG) shares moved up 14.52% to $16.09 at 10:50 am. The volume of AMAG shares traded was 519% higher than normal. AMAG has reached an agreement with the FDA about labeling for its anemia treatment. Amtech Systems Inc (NASDAQ: ASYS) shares rose 5.13% to $20.96. The...
-
Options Brief: AMAG Pharmaceuticals (AMAG)
Monday, November 29, 2010 - 11:14am | 96Shares of AMAG Pharmaceuticals (NASDAQ: AMAG) are higher on the session by 13.59%, currently trading at $15.96. Put volume is now running at 5.94x the daily average, with 1% of all puts traded being purchases on the offer. 2,644 put contracts have traded so far during the session. AMAG...
-
Amylin Stays Neutral - Analyst Blog
Wednesday, November 24, 2010 - 1:12pm | 621We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year ago loss of $0.19. Lower revenues resulted in the wider loss...
-
Amylin Stays Neutral - Analyst Blog
Wednesday, November 24, 2010 - 7:20am | 621We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year ago loss of $0.19. Lower revenues resulted in the wider loss...
-
Options Brief: AMAG Pharmaceuticals (AMAG)
Tuesday, November 23, 2010 - 1:37pm | 90Shares of AMAG Pharmaceuticals (NASDAQ: AMAG) are lower on the session by 0.78%, trading at $14.01. Overall put volume is now running at 7.87x the daily average, with 27% of all puts traded being purchases on the offer. 2,559 contracts have traded on the session so far. AMAG Pharmaceuticals, Inc....
-
Calls Purchased on Medivation (MDVN)
Monday, November 22, 2010 - 4:31pm | 152Shares of Medivation (NASDAQ: MDVN) are higher on the session by 0.45%, currently trading at $11.27. The stock has been moving largely higher over the past three months, though it is currently trading below the 50-day and 200-day moving averages. Options traders are buying calls on the name today...
-
Options Brief: Bruker Corporation (BRKR)
Monday, November 22, 2010 - 11:10am | 106Shares of Bruker Corporation (NASDAQ: BRKR) are higher on the session by 2.53%, trading at $15.81. Overall call volume is now running at 19.94x the daily average, with 0% of all calls traded being purchases on the offer. 2,014 contracts have traded on the session so far. Bruker Corporation is a...
-
New Diagnostic Test from Luminex - Analyst Blog
Thursday, November 18, 2010 - 1:33pm | 737Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an...
-
Morning Market Movers (LTXC, EXEL, MPB, BSPM)
Thursday, November 18, 2010 - 11:11am | 124LTX-Credence Corporation (NASDAQ: LTXC) jumped 31.10% to $7.84 at 10:10 am. LTXC is all set to report its Q1 results on November 23. Exelixis Inc (NASDAQ: EXEL) climbed 26.06% to $5.95. EXEL has reported interim data from the patients with metastatic castration-resistant prostate cancer (CRPC)...
-
Benzinga's Top Pre-Market NASDAQ Gainers (EXEL, DNDN, DRYS, ARUN)
Thursday, November 18, 2010 - 9:19am | 123Exelixis Inc (NASDAQ: EXEL) rose 20.13% to $5.67 in the pre-market session. EXEL has reported interim data from the patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184. Dendreon Corporation (NASDAQ: DNDN) added 9.14% to $39.15 in the pre-market session. A US...
-
Piper Jaffray Overweight On Exelixis (EXEL)
Thursday, November 18, 2010 - 8:29am | 112Piper Jaffray has an Overweight rating on Exelixis, Inc. (NASDAQ: EXEL) and a $9 price target on the stock. In a research report sent to clients, Piper Jaffray writes, "Today at the EORTC meeting in Berlin, Exelixis presented 6 posters on the on-going Phase II randomized discontinuation trial (RDT...
-
New Diagnostic Test from Luminex - Analyst Blog
Thursday, November 18, 2010 - 8:10am | 737Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an...
-
Luminex Corporation Authorizes Repurchase Plan of 1M Shares
Wednesday, November 17, 2010 - 5:11pm | 44Luminex Corporation (Nasdaq: LMNX) today announced that the company's Board of Directors has authorized the purchase of up to 1,000,000 shares, but not more than $21 million in aggregate purchase price, of the company's common stock through November 2011.
-
Pressure BioSciences (PBIO) Reports Strong Third Quarter Financial Results - Analyst Blog
Wednesday, November 17, 2010 - 11:33am | 903Grant Zeng, CFA On November 16, 2010, Pressure BioSciences, Inc. (PBIO) reported financial results for the third quarter ended September 30, 2010. Total revenue for 3Q10 was $372,103 compared to $317,427 for the comparable period in 2009, a 17% increase. Sales from PCT products and services...